HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FTC Does Advertising Law Enforcement, Not Second Chances For Ad Claims Arbitration

Executive Summary

Some firms that challenged ad claims NAD attorneys later bring to FTC's attention want to take more shots at the claims while businesses making the claims want to repeat their arguments from NAD reviews, says Carolyn Hann, FTC chief of staff for advertising practices.

You may also be interested in...



Immunity, Weight Loss Supplement Marketers Risk FTC Scrutiny By Ignoring Industry Self-Regulation

NAD forwards to regulatory agency its concerns about claims by Hypernatural and Letitox Nutrition after they didn’t participate in the industry self-regulation forum. Both firms’ claims were challenged by the Council for Responsible Nutrition as part of a program with NAD it previously supported.

Industry Self-Regulation Group’s Knowledge Of Drug Types Questioned By US Homeopathic Firm

Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.

P&G Health, Hygiene Brands Ride Consumer ‘Trust’ To Sales Growth Amid Pandemic Uncertainty

“There’s a heightened need for products that deliver against health, hygiene and clean home concerns and a willingness to spend just a little bit more to ensure that I’m using a product that I know and trust,” says CFO Jon Moeller 

Topics

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel